Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 juin 2017 07h30 HE | Source: Otonomy, Inc.

Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes

SAN DIEGO, June 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
20 juin 2017 07h30 HE | Source: Otonomy, Inc.

Otonomy to Host Key Opinion Leader Meeting for Investors on Ménière's Disease

SAN DIEGO, June 20, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
12 mai 2017 07h30 HE | Source: Otonomy, Inc.

Otonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting

SAN DIEGO, May 12, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
10 mai 2017 16h05 HE | Source: Otonomy, Inc.

Otonomy to Present at the Bank of America Merrill Lynch Health Care Conference

SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
04 mai 2017 16h27 HE | Source: Otonomy, Inc.

Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
27 avr. 2017 16h05 HE | Source: Otonomy, Inc.

Otonomy to Report First Quarter 2017 Financial Results and Provide Corporate Update

SAN DIEGO, April 27, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
02 mars 2017 16h18 HE | Source: Otonomy, Inc.

Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

Topline data for OTO-104 Phase 3 trials in Ménière’s disease expected in 2H2017 Implemented changes to commercial organization to improve OTIPRIO® sales performance Company to host conference call...
28 févr. 2017 16h05 HE | Source: Otonomy, Inc.

Otonomy to Present at Cowen and Company Health Care Conference

SAN DIEGO, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
24 févr. 2017 07h30 HE | Source: Otonomy, Inc.

Otonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
19 janv. 2017 07h30 HE | Source: Otonomy, Inc.

Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss

SAN DIEGO, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...

Page précédente